Long-Term Outcome of B-CLL Patients Treated in a Prospective Trial Evaluating Combination of Oral Fludarabine and Cyclophosphamide As Frontline Therapy

被引：0
|
作者：
Guieze, Romain [1 ]
Tournilhac, Olivier [2 ]
Maloum, Karim [3 ]
Lepretre, Stephane [4 ]
Haioun, Corinne [5 ]
Feugier, Pierre [6 ]
Delmer, Alain [7 ]
Leporrier, Michel [8 ]
Cazin, Bruno [9 ]
机构：
[1] CHU Estaing, Clermont Ferrand, France
[2] Ctr Hosp Univ Clermont Ferrand, Clermont Ferrand, France
[3] Hop La Pitie Salpetriere, Paris, France
[4] Ctr Henri Becquerel, F-76038 Rouen, France
[5] APHP Henri Mondor, Creteil, France
[6] Hop Adultes Brabois, Serv Hematol, Vandoeuvre Les Nancy, France
[7] Hop Robert Debre, CHU Reims Hematol, Reims, France
[8] CHU Caen, F-14000 Caen, France
[9] Ctr Hosp Reg Univ Lille, Serv Malad Sang, Lille, France
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：783 / 783
页数：1
相关论文
共 50 条
  • [1] Prognostic significance of immunoglobulin variable region mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide
    Nikitin, E. A.
    Stadnik, E. A.
    Yu, Lorie Yu.
    Biderman, B., V
    Tsyba, N. N.
    Salogub, G. N.
    Kolosheinova, T., I
    Kolosova, L. Yu
    Risinskaya, N. A.
    Zaritsky, Yu. A.
    Kovaleva, L. G.
    Sudarikov, A. B.
    TERAPEVTICHESKII ARKHIV, 2007, 79 (07) : 66 - 70
  • [2] Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)
    Tam, Constantine S.
    O'Brien, Susan
    Plunkett, William
    Wierda, William
    Ferrajoli, Alessandra
    Wang, Xuemei
    Do, Kim-Anh
    Cortes, Jorge
    Khouri, Issa
    Kantarjian, Hagop
    Lerner, Susan
    Keating, Michael J.
    BLOOD, 2014, 124 (20) : 3059 - 3064
  • [3] Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia
    Feugier, Pierre
    Aurran, Therese
    Mahe, Beatrice
    Letestu, Remi
    Nguyen-Khac, Florence
    Cazin, Bruno
    Tournilhac, Olivier
    Maisonneuve, Herve
    Casasnovas, Olivier
    Delmer, Alain
    Leblond, Veronique
    Royer, Bruno
    Corront, Bernadette
    Chevret, Sylvie
    Delepine, Roselyne
    Vaudaux, Sandrine
    Van den Neste, Eric
    Bene, Marie-Christine
    Cymbalista, Florence
    Ross-Weil, Damien
    Lepretre, Stephane
    HAEMATOLOGICA, 2018, 103 (07) : E304 - E306
  • [4] Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome
    De Padua, Laura
    Laurenti, Luca
    Falcucci, Paolo
    D'arena, Giovanni
    Vannata, Barbara
    Innocenti, Idanna
    Autore, Francesco
    Piccirillo, Nicola
    Za, Tommaso
    Marietti, Sara
    Efremov, Dimitar G.
    Sica, Simona
    ANNALS OF HEMATOLOGY, 2014, 93 (07) : 1261 - 1262
  • [5] Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome
    Laura De Padua
    Luca Laurenti
    Paolo Falcucci
    Giovanni D’arena
    Barbara Vannata
    Idanna Innocenti
    Francesco Autore
    Nicola Piccirillo
    Tommaso Za
    Sara Marietti
    Dimitar G Efremov
    Simona Sica
    Annals of Hematology, 2014, 93 : 1261 - 1262
  • [6] Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)
    Fink, Anna
    Busch, Raymonde
    Pflug, Natali
    Boettcher, Sebastian
    Winkler, Dirk
    Buehler, Andreas
    Ritgen, Matthias
    Fischer, Kirsten
    Eichhorst, Barbara
    Wendtner, Clemens-Martin
    Mendila, Myriam
    Wenger, Michael K.
    Doehner, Hartmut
    Kneba, Michael
    Stilgenbauer, Stephan
    Hallek, Michael
    BLOOD, 2011, 118 (21) : 446 - 447
  • [7] Long-term outcome in lupus nephritis patients treated with intravenous cyclophosphamide
    Gonzalez-Crespo, Maria R.
    Mateo Bernardo, Isabel
    RHEUMATOLOGY, 2001, 40 : 110 - 110
  • [8] Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
    Castagnetti, F.
    Gugliotta, G.
    Breccia, M.
    Stagno, F.
    Iurlo, A.
    Albano, F.
    Abruzzese, E.
    Martino, B.
    Levato, L.
    Intermesoli, T.
    Pregno, P.
    Rossi, G.
    Gherlinzoni, F.
    Leoni, P.
    Cavazzini, F.
    Venturi, C.
    Soverini, S.
    Testoni, N.
    Alimena, G.
    Cavo, M.
    Martinelli, G.
    Pane, F.
    Saglio, G.
    Rosti, G.
    Baccarani, M.
    LEUKEMIA, 2015, 29 (09) : 1823 - 1831
  • [9] Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
    F Castagnetti
    G Gugliotta
    M Breccia
    F Stagno
    A Iurlo
    F Albano
    E Abruzzese
    B Martino
    L Levato
    T Intermesoli
    P Pregno
    G Rossi
    F Gherlinzoni
    P Leoni
    F Cavazzini
    C Venturi
    S Soverini
    N Testoni
    G Alimena
    M Cavo
    G Martinelli
    F Pane
    G Saglio
    G Rosti
    M Baccarani
    Leukemia, 2015, 29 : 1823 - 1831
  • [10] Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia
    Souchet, Laetitia
    Levy, Vincent
    Ouzegdouh, Maya
    Tamburini, Jerome
    Delmer, Alain
    Dupuis, Jehan
    Le Gouill, Steven
    Pegourie-Bandelier, Brigitte
    Tournilhac, Olivier
    Boubaya, Marouanne
    Vargaftig, Jacques
    Choquet, Sylvain
    Leblond, Veronique
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (08) : 782 - 786
12345